Evolution of a strain of CJD that induces BSE-like plaques

Science

Volumn 277, Issue 5322, 1997, Pages 94-98

  Manuelidis, Laura ^a   Fritch, William ^a   Xi, You Gen ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BOVINE SPONGIFORM ENCEPHALOPATHY; CELL VACUOLE; CEREBELLUM INJURY; CREUTZFELDT JAKOB DISEASE; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; BRAIN; BRAIN CHEMISTRY; CEREBELLUM; CLUSTERIN; CREUTZFELDT-JAKOB SYNDROME; CRICETINAE; CRICETULUS; ENCEPHALOPATHY, BOVINE SPONGIFORM; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOPROTEINS; INFLAMMATION; MACROPHAGES; MICE; MICE, INBRED STRAINS; MICROGLIA; MICROSCOPY, ELECTRON; MOLECULAR CHAPERONES; PRPSC PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RNA; TIME FACTORS; UBIQUITINS; VACUOLES; VIRULENCE;

EID: 0030758270     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.277.5322.94     Document Type: Article

References (72)

1. R. Andersen et al., Nature 382, 779 (1996).
2. M. Dawson, G. Wells, B. Parker, A. Scott, Vet. Rec. 127, 338 (1990); M. Bruce et al. Philos. Trans. R. Soc. London Ser. B 343, 405 (1994).
3. M. Dawson, G. Wells, B. Parker, A. Scott, Vet. Rec. 127, 338 (1990); M. Bruce et al. Philos. Trans. R. Soc. London Ser. B 343, 405 (1994).
4. C. Lasemézas et al., Nature 381, 733 (1996); A. Aguzzi, ibid., p. 734.
5. C. Lasemézas et al., Nature 381, 733 (1996); A. Aguzzi, ibid., p. 734.
6. R. Will et al., Lancet 347, 921 (1996).
7. L. Manuelidis, Transfusion 34, 915 (1994).
8. _, J. NeuroVirol. 3, 62 (1997).
9. I. Pattison and G. Millson, J. Comp. Pathol. 75, 147 (1961); I. Pattison, Res. Vet. Sci. 7, 207 (1966); M. E. Bruce and A. G. Dickinson, J. Gen. Virol. 68, 79 (1987).
10. I. Pattison and G. Millson, J. Comp. Pathol. 75, 147 (1961); I. Pattison, Res. Vet. Sci. 7, 207 (1966); M. E. Bruce and A. G. Dickinson, J. Gen. Virol. 68, 79 (1987).
11. I. Pattison and G. Millson, J. Comp. Pathol. 75, 147 (1961); I. Pattison, Res. Vet. Sci. 7, 207 (1966); M. E. Bruce and A. G. Dickinson, J. Gen. Virol. 68, 79 (1987).
12. L. Manuelidis, in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 375-387.
13. D. C. Gajdusek, Science 197, 943 (1977).
14. E. E. Manuelidis, ibid. 190, 571 (1975); E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Nature 271, 778 (1978); Proc. Natl. Acad. Sci. U.S.A. 75, 3432 (1978); J. Tateishi, T. Kitamoto, M. Hoque, H. Furukawa, Neurology 46, 532 (1996).
15. E. E. Manuelidis, ibid. 190, 571 (1975); E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Nature 271, 778 (1978); Proc. Natl. Acad. Sci. U.S.A. 75, 3432 (1978); J. Tateishi, T. Kitamoto, M. Hoque, H. Furukawa, Neurology 46, 532 (1996).
16. E. E. Manuelidis, ibid. 190, 571 (1975); E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Nature 271, 778 (1978); Proc. Natl. Acad. Sci. U.S.A. 75, 3432 (1978); J. Tateishi, T. Kitamoto, M. Hoque, H. Furukawa, Neurology 46, 532 (1996).
17. E. E. Manuelidis, ibid. 190, 571 (1975); E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Nature 271, 778 (1978); Proc. Natl. Acad. Sci. U.S.A. 75, 3432 (1978); J. Tateishi, T. Kitamoto, M. Hoque, H. Furukawa, Neurology 46, 532 (1996).
18. The plaque-rich GSS cases include several different PrP mutations and variable transmissibility [P. Brown, Rev. Neurol. 148, 317 (1992); B. Ghetti et al., Sem. Virol. 7, 189 (1996) and reviewed in (5)].
19. The plaque-rich GSS cases include several different PrP mutations and variable transmissibility [P. Brown, Rev. Neurol. 148, 317 (1992); B. Ghetti et al., Sem. Virol. 7, 189 (1996) and reviewed in (5)].
20. G. Telling et al., Science 274, 2079 (1996). The congophilic plaques described in P1 mice and rats from this progenitor strain were associated with the inoculation site and adjacent subependyma and white matter but were not reproduced on serial passage [J. Tateishi, H. Nagara, K. Hikita, Y. Sato, Ann. Neurol. 15, 278 (1984)].
21. G. Telling et al., Science 274, 2079 (1996). The congophilic plaques described in P1 mice and rats from this progenitor strain were associated with the inoculation site and adjacent subependyma and white matter but were not reproduced on serial passage [J. Tateishi, H. Nagara, K. Hikita, Y. Sato, Ann. Neurol. 15, 278 (1984)].
22. 129 homozygosity, a polymorphism present in 38% of the human population.
23. P. Brown, in Immunologic Mechanisms in Neurologic and Psychiatric Disease, B. Waksman, Ed. (Raven, New York, 1990), pp. 305-313; S. Prusiner, Sci. Am. 272, 30 (January 1995).
24. P. Brown, in Immunologic Mechanisms in Neurologic and Psychiatric Disease, B. Waksman, Ed. (Raven, New York, 1990), pp. 305-313; S. Prusiner, Sci. Am. 272, 30 (January 1995).
25. L. Manuelidis and W. Fritch, Virology 215, 46 (1996). The fastest strain will preferentially survive during the >15-year passage. Because the determined doubling time is 7.5 days, each year of continuous passage (two or more per year) represents ∼248 doublings. Additionally, cross-species transmission can mimic strain selection by limiting dilution (7), because P1 incubation times and "takes" correspond to about one infectious dose.
26. Sprague-Dawley rats were inoculated intracerebrally with 50 μl of a 10% SY-infected hamster brain. For serial passage, a slice of rat frontal cortex was homogenized. Five-micrometer deparafinized sections were used for antibody binding with standard alkaline phosphatase or peroxidase detectors. Primary antibodies were diluted >1:1000, except HLA-DR, which was diluted 1:300. Because standard methods for histological detection of PrPres (hydrolytic autoclaving, formic acid treatment, and proteinase K digestion) produced artifactual vacuoles, we developed other pretreatments. Autoclaving 5-m paraffin sections for 12 min in 0.2 M citrate (pH 6.0) preserved neuropil structure, gave little PrP background in controls, and did not alter the staining pattern of other antibodies in double detections. For double labeling, polyclonal antibody P8-1 (against gel-purified PrP-res) was first detected with peroxidase development (∼5 min) with alakaline phosphatase for the second mononclonal antibody (∼5 min). Reversed detection showed the same pattern of labeling.
27. Normally, microglia are found around vessels but rarely within the grey parenchyma, and we used a KS antibody to delineate activated microglia. In accord with Fig. 1B, KS antibody to released chondroitin sulfate (clone 5D4; ICN Costa Mesa, CA) can stain a few "ramified" microglia in the normal rat cortex [A. Bertolotto et al., J. Histochem. Cytochem. 41, 481 (1993)]. The numerous reactive microglia in infected rats were enlarged and had many processes, making them morphologically comparable to activated HLA-DR (class II) microglia in Alzheimer's disease (25). Additionally, invariant chains (associated with major histocompatibility class II molecules in antigen presentation) are modified by chondroitin sulfate [M. F. Naujokas et al., Cell 74, 245 (1993)]. It has not yet been determined whether the increase in activated microglia shown here represents migrating or proliferating populations; the association of many KS microglia with thin-walled vessels in later passages could suggest entry (macrophage derivatives) from the bloodstream. Some KS-positive cells may be phagocytic as PrP-res increased in the cytoplasm at later passages, but these cells were negative for the macrophage marker ED-1.
28. Normally, microglia are found around vessels but rarely within the grey parenchyma, and we used a KS antibody to delineate activated microglia. In accord with Fig. 1B, KS antibody to released chondroitin sulfate (clone 5D4; ICN Costa Mesa, CA) can stain a few "ramified" microglia in the normal rat cortex [A. Bertolotto et al., J. Histochem. Cytochem. 41, 481 (1993)]. The numerous reactive microglia in infected rats were enlarged and had many processes, making them morphologically comparable to activated HLA-DR (class II) microglia in Alzheimer's disease (25). Additionally, invariant chains (associated with major histocompatibility class II molecules in antigen presentation) are modified by chondroitin sulfate [M. F. Naujokas et al., Cell 74, 245 (1993)]. It has not yet been determined whether the increase in activated microglia shown here represents migrating or proliferating populations; the association of many KS microglia with thin-walled vessels in later passages could suggest entry (macrophage derivatives) from the bloodstream. Some KS-positive cells may be phagocytic as PrP-res increased in the cytoplasm at later passages, but these cells were negative for the macrophage marker ED-1.
29. L. Manuelidis, D. M. Tesin, T. Sklaviadis, E. E. Manuelidis, Proc. Natl. Acad. Sci. U.S.A. 84, 5937 (1987).
30. E. E. Manuelidis, J. Kim, J. Angelo, L. Manuelidis, ibid. 73, 223 (1976).
31. At early stages of clinical disease (∼307 days), rats could not right themselves when hung on a cage grid upside down. About a week later, a footprint test documented tight circling and wobbling, whereas older control rats ran straight off the filter paper. As in P1 and P2, terminal rats were hunched and thin, with ruffled fur.
32. H. M. Wisniewski, M. E. Bruce, H. Fraser, Science 190, 1108 (1975). Rat plaques with "very faint" Congo Red birefringence [E. Field, C. Raine, G. Joyce, Acta Neuropathol. 8, 47 (1967)] and in three aged Sprague-Dawley rats [D. Vaughan and A. Peters, J. Neuropath. Exp. Neurol. 40, (1981)] have not been reproducible. Moreover, many other scrapie isolates propagated in rats (7) [R. Kimberlin, S. Cole, C. Walker, J. Gen. Virol. 68, 1875 (1987)] have shown only short incubation times (<200 days) and vacuolar change. In contrast, the plaques here developed only after serial propagation and were widespread and unrelated to the inoculation site.
33. H. M. Wisniewski, M. E. Bruce, H. Fraser, Science 190, 1108 (1975). Rat plaques with "very faint" Congo Red birefringence [E. Field, C. Raine, G. Joyce, Acta Neuropathol. 8, 47 (1967)] and in three aged Sprague-Dawley rats [D. Vaughan and A. Peters, J. Neuropath. Exp. Neurol. 40, (1981)] have not been reproducible. Moreover, many other scrapie isolates propagated in rats (7) [R. Kimberlin, S. Cole, C. Walker, J. Gen. Virol. 68, 1875 (1987)] have shown only short incubation times (<200 days) and vacuolar change. In contrast, the plaques here developed only after serial propagation and were widespread and unrelated to the inoculation site.
34. H. M. Wisniewski, M. E. Bruce, H. Fraser, Science 190, 1108 (1975). Rat plaques with "very faint" Congo Red birefringence [E. Field, C. Raine, G. Joyce, Acta Neuropathol. 8, 47 (1967)] and in three aged Sprague-Dawley rats [D. Vaughan and A. Peters, J. Neuropath. Exp. Neurol. 40, (1981)] have not been reproducible. Moreover, many other scrapie isolates propagated in rats (7) [R. Kimberlin, S. Cole, C. Walker, J. Gen. Virol. 68, 1875 (1987)] have shown only short incubation times (<200 days) and vacuolar change. In contrast, the plaques here developed only after serial propagation and were widespread and unrelated to the inoculation site.
35. H. M. Wisniewski, M. E. Bruce, H. Fraser, Science 190, 1108 (1975). Rat plaques with "very faint" Congo Red birefringence [E. Field, C. Raine, G. Joyce, Acta Neuropathol. 8, 47 (1967)] and in three aged Sprague-Dawley rats [D. Vaughan and A. Peters, J. Neuropath. Exp. Neurol. 40, (1981)] have not been reproducible. Moreover, many other scrapie isolates propagated in rats (7) [R. Kimberlin, S. Cole, C. Walker, J. Gen. Virol. 68, 1875 (1987)] have shown only short incubation times (<200 days) and vacuolar change. In contrast, the plaques here developed only after serial propagation and were widespread and unrelated to the inoculation site.
36. H. Gomi et al., Neurosci. Lett. 166, 171 (1994); R. Riek et al., Nature 382, 180 (1996). Alignment of GenBank sequences also shows only a single lle-to-Leu difference in rat versus mice at codon 139.
37. H. Gomi et al., Neurosci. Lett. 166, 171 (1994); R. Riek et al., Nature 382, 180 (1996). Alignment of GenBank sequences also shows only a single lle-to-Leu difference in rat versus mice at codon 139.
38. For time course experiments, two random rats were killed and the uninoculated halves of the brains were fixed in formalin (16). Submitted images and controls for ubiquitin, ApoJ, APLP, and ApoE will be reported in detail elsewhere (27). The other halves were used for blots. A small slice of unfixed cerebellum and cortex from each brain was pooled and homogenized in saline for studies of PrP on blots, whereas the remaining unfixed half-brains were used for isolation of RNA and Northern (RNA) blotting as described (18). Proteinase K production of PrP-res was optimized for yield and maximum detection sensitivity by quantitative chemiluminesce (15). With polyclonal P8-1 diluted 1:2400, longer exposures made 1 in 20,000 PrP molecules visually obvious whereas 16-bit digitization with standards indicated a detection sensitivity approaching 5 logs. Use of other antibodies to PrP peptides gave the same pattern of PrP-res accumulation.
39. The slightly lesser value for KS microglia as compared with that for vacuoles at 150 days is due to our exclusion of vacuolated cerebellum in scoring, be cause the internal granule layer normally contains some KS+ cells.
40. P. McGeer, S. Akiyama, S. ltagaki, E. McGeer, Can. J. Neural. Sci. 16, 516 (1989); P. McGeer, K. Kawamata, D. Walker, Brain Res. 579, 337 (1992).
41. P. McGeer, S. Akiyama, S. ltagaki, E. McGeer, Can. J. Neural. Sci. 16, 516 (1989); P. McGeer, K. Kawamata, D. Walker, Brain Res. 579, 337 (1992).
42. H. Slunt et al., J. Biol. Chem. 269, 2637 (1994); B. Crain et al., Am. J. Pathol. 149, 1087 (1996).
43. H. Slunt et al., J. Biol. Chem. 269, 2637 (1994); B. Crain et al., Am. J. Pathol. 149, 1087 (1996).
44. L. Manuelidis, in preparation.
45. J. Collinge, K. Sidle, J. Meads, J. Ironside, A. Hill, Nature 383, 685 (1996).
46. L. Manuelidis, T. Sklaviadis, E. E. Manuelidis, EMBO J. 6, 341 (1987).
47. C. I. Lasmézas et al., Science 275, 402 (1997).
48. A. Akowitz, T. Sklaviadis, E. E. Manuelidis, L. Manuelidis, Microb. Pathog. 9, 33 (1990); T. Sklaviadis, R. Dreyer, L. Manuelidis, Virus Res. 26, 241 (1992); T. Sklaviadis, A. Akowitz, E. E. Manuelidis, L. Manuelidis, Arch. Virol. 112, 215 (1990); M. Ozel, E. Baldauf, M. Beekes, H. Diringer, in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 369-373.
49. A. Akowitz, T. Sklaviadis, E. E. Manuelidis, L. Manuelidis, Microb. Pathog. 9, 33 (1990); T. Sklaviadis, R. Dreyer, L. Manuelidis, Virus Res. 26, 241 (1992); T. Sklaviadis, A. Akowitz, E. E. Manuelidis, L. Manuelidis, Arch. Virol. 112, 215 (1990); M. Ozel, E. Baldauf, M. Beekes, H. Diringer, in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 369-373.
50. A. Akowitz, T. Sklaviadis, E. E. Manuelidis, L. Manuelidis, Microb. Pathog. 9, 33 (1990); T. Sklaviadis, R. Dreyer, L. Manuelidis, Virus Res. 26, 241 (1992); T. Sklaviadis, A. Akowitz, E. E. Manuelidis, L. Manuelidis, Arch. Virol. 112, 215 (1990); M. Ozel, E. Baldauf, M. Beekes, H. Diringer, in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 369-373.
51. A. Akowitz, T. Sklaviadis, E. E. Manuelidis, L. Manuelidis, Microb. Pathog. 9, 33 (1990); T. Sklaviadis, R. Dreyer, L. Manuelidis, Virus Res. 26, 241 (1992); T. Sklaviadis, A. Akowitz, E. E. Manuelidis, L. Manuelidis, Arch. Virol. 112, 215 (1990); M. Ozel, E. Baldauf, M. Beekes, H. Diringer, in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 369-373.
52. L. Manuelidis, T. Sklaviadis, A. Akowitz, W. Fritch, Proc. Natl. Acad. Sci. U.S.A. 92, 5124 (1995).
53. M. Dron and L. Manuelidis, J. Neurovirol. 2, 240 (1996).
54. K. K. Hsiao et al., Ann. N.Y. Acad. Sci. 724, 241 (1994); L. Manuelidis, ibid., p. 259; R. I. Carp et al., Trends Neurosci. 17, 148 (1994); R. E. Race et al., Neuron 15, 1183 (1995).
55. K. K. Hsiao et al., Ann. N.Y. Acad. Sci. 724, 241 (1994); L. Manuelidis, ibid., p. 259; R. I. Carp et al., Trends Neurosci. 17, 148 (1994); R. E. Race et al., Neuron 15, 1183 (1995).
56. K. K. Hsiao et al., Ann. N.Y. Acad. Sci. 724, 241 (1994); L. Manuelidis, ibid., p. 259; R. I. Carp et al., Trends Neurosci. 17, 148 (1994); R. E. Race et al., Neuron 15, 1183 (1995).
57. K. K. Hsiao et al., Ann. N.Y. Acad. Sci. 724, 241 (1994); L. Manuelidis, ibid., p. 259; R. I. Carp et al., Trends Neurosci. 17, 148 (1994); R. E. Race et al., Neuron 15, 1183 (1995).
58. F. Tagliavini et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 323-327; D. R. Brown, B. Schmidt, H. A. Kretzschmar, Nature 380, 345 (1996).
59. F. Tagliavini et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 323-327; D. R. Brown, B. Schmidt, H. A. Kretzschmar, Nature 380, 345 (1996).
60. H. Büeler et al., Cell 73, 1339 (1993); S. Sakaguchi et al., J. Virol. 69, 7586 (1995).
61. H. Büeler et al., Cell 73, 1339 (1993); S. Sakaguchi et al., J. Virol. 69, 7586 (1995).
62. H. Diringer and B. Ehlers, J. Gen. Virol. 72, 457 (1991).
63. E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Science 200, 1069 (1978); E. E. Manuelidis, J. H. Kim, J. R. Mericangas, L. Manuelidis, Lancet ii, 896 (1985); J. Tateishi, ibid., p. 1074; H. Diringer, Arch. Virol. 82, 105 (1984).
64. E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Science 200, 1069 (1978); E. E. Manuelidis, J. H. Kim, J. R. Mericangas, L. Manuelidis, Lancet ii, 896 (1985); J. Tateishi, ibid., p. 1074; H. Diringer, Arch. Virol. 82, 105 (1984).
65. E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Science 200, 1069 (1978); E. E. Manuelidis, J. H. Kim, J. R. Mericangas, L. Manuelidis, Lancet ii, 896 (1985); J. Tateishi, ibid., p. 1074; H. Diringer, Arch. Virol. 82, 105 (1984).
66. E. E. Manuelidis, E. J. Gorgacz, L. Manuelidis, Science 200, 1069 (1978); E. E. Manuelidis, J. H. Kim, J. R. Mericangas, L. Manuelidis, Lancet ii, 896 (1985); J. Tateishi, ibid., p. 1074; H. Diringer, Arch. Virol. 82, 105 (1984).
67. S. Betmouni, V. Perry, J. Gordon, Neuroscience 74, 1 (1996); C. I. Lasmézas et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 151-157; G. Outram, in Slow Virus Diseases of Animals and Man, R. Kimberlin, Ed. (North-Holland, Amsterdam, 1976); R. Kimberlin and P. Cunnington,Microbiol. Lett. 3, 169-(1978); A. Fauci, Nature 384, 529 (1996).
68. S. Betmouni, V. Perry, J. Gordon, Neuroscience 74, 1 (1996); C. I. Lasmézas et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 151-157; G. Outram, in Slow Virus Diseases of Animals and Man, R. Kimberlin, Ed. (North-Holland, Amsterdam, 1976); R. Kimberlin and P. Cunnington,Microbiol. Lett. 3, 169-(1978); A. Fauci, Nature 384, 529 (1996).
69. S. Betmouni, V. Perry, J. Gordon, Neuroscience 74, 1 (1996); C. I. Lasmézas et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 151-157; G. Outram, in Slow Virus Diseases of Animals and Man, R. Kimberlin, Ed. (North-Holland, Amsterdam, 1976); R. Kimberlin and P. Cunnington,Microbiol. Lett. 3, 169-(1978); A. Fauci, Nature 384, 529 (1996).
70. S. Betmouni, V. Perry, J. Gordon, Neuroscience 74, 1 (1996); C. I. Lasmézas et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 151-157; G. Outram, in Slow Virus Diseases of Animals and Man, R. Kimberlin, Ed. (North-Holland, Amsterdam, 1976); R. Kimberlin and P. Cunnington,Microbiol. Lett. 3, 169-(1978); A. Fauci, Nature 384, 529 (1996).
71. S. Betmouni, V. Perry, J. Gordon, Neuroscience 74, 1 (1996); C. I. Lasmézas et al., in Transmisssible Subacute Spongiform Encephalopathies: Prion Diseases, L. Court and B. Dodet, Eds. (Elsevier, Paris, 1996), pp. 151-157; G. Outram, in Slow Virus Diseases of Animals and Man, R. Kimberlin, Ed. (North-Holland, Amsterdam, 1976); R. Kimberlin and P. Cunnington,Microbiol. Lett. 3, 169-(1978); A. Fauci, Nature 384, 529 (1996).
72. We thank I. Shvayetsky, Z. Y. Lu for technical assistance, and I. Alafuzoff for suggesting citrate autoclaving. The human GSS and BSE blocks were generously provided by J. Tateishi and J. Ironside, respectively. Supported by NIH grants NS12674 and NS34569.